Long-term Safety and Efficacy of Deucravacitinib in Participants with Crohn's Disease or Ulcerative Colitis

An Open-label, Multi-center Extension Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants with Moderate to Severe Crohn's Disease or Moderate to Severe Ulcerative Colitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210637

Enrollment

Registered

2022-03-02

Start date

2022-03-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Crohn's Disease or Moderate to Severe Ulcerative Colitis

Interventions

BMS-986165(Deucravacitinib) 6 mg BID

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Previously completed OLE treatment in 1 of the parent CD or UC studies

Exclusion criteria

Exclusion criteria: Any disease or medical condition that, in the opinion of the investigator, would make the participant unsuitable for this study, would interfere with the interpretation of participant safety or study results, or is considered unsuitable by the investigator for any other reason.

Design outcomes

Primary

Measure	Time frame
To assess the safety and tolerability of long-term use of BMS-986165(Deucravacitinib)	—

Secondary

Measure	Time frame
To assess the effect of long-term use of BMS-986165(Deucravacitinib)	—

Countries

Australia, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Romania, Russia, South Korea, Spain, Switzerland, Taiwan, UK, US

Contacts

Public ContactElsharkawi Walid

Bristol-Myers Squibb

MG-JP-RCO-JRCT@bms.com+81-120-093-507

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026